cdk4/6 inhibitors in the first-line treatment setting
Published 9 years ago • 324 plays • Length 7:40Download video MP4
Download video MP3
Similar videos
-
5:57
cdk4/6 inhibitors in the second-line treatment setting
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
7:13
the biological rationale for cdk4/6 inhibitors
-
5:16
the clinical potential of cdk4/6 inhibitors
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
6:09
ongoing trials of cdk4/6 inhibitors
-
53:15
will new antibody drug conjugates cure bladder cancer?
-
21:08
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - second-line therapy
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
15:06
mechanistic activity and development history of cdk 4/6 inhibitors
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
9:42
expert perspectives: rationale for cdk 4/6 inhibition in breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
14:51
expert perspectives: targeting advanced er metastatic breast cancer with cdk 4/6 inhibitors
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:37
dr. han on the differences between cdk 4/6 inhibitors in er breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
6:41
differences among cdk4/6 inhibitors in hr mbc